

COVACTA – Rosas, IO; et al. NEJM 2021 (Published: Sep 25, 2021)

Study Design	Multicenter, double-blind, placebo, RCT – Severe/Critical COVID-19 – (2:1)	
Location	Global – 9 countries	
Inclusion	Severe/Critical COVID-19 pneumonia + SpO ₂ < 93% or with PaO ₂ /FiO ₂ ratio <300	
Exclusion	If O ₂ requirement >10L/min	
Intervention	Tocilizumab 8 mg/kg IV (up to 800 mg)	
Control	Placebo	
	Tocilizumab n=294	Control n=144
Primary Outcomes		
7-category ordinal scale# at day 28, median value	1.0	2.0
7-category ordinal scale# clinical status at day 14, median value	3.0	4.0
MV	51/183 (27.9%)	33/90 (36.7%)
ICU stay, days	9.8	15.5
Time to hospital discharge, days	20	28
Death at day 28	19.7%	19.4%
Comments: # 7-level ordinal scale (1, discharged/ready for discharge; 7, death) Corticosteroids at baseline in 19.4% in the toci arm and 28.5% in the control arm.		
Abbreviations: ICU, intensive care unit; MV, mechanical ventilation; O ₂ , oxygen; RCT, randomized controlled trial.		